From Dog

Temozolomide is a imidazotetrazine methylating alkylating agent used for chemotherapy in dogs[1].

This drug has been used in combination with dacarbazine as a rescue remedy for canine lymphoma[2] and metastatic malignant melanoma[3].

The minimum lethal dose in dogs was 600 mg/m2 and in multiple-cycle studies, the primary targets of toxicity included bone marrow, lymphoreticular system, testes and gastrointestinal tract.

Recommended dose rate is 75 mg/m2 given orally once daily 42 days.


  1. Gori JL et al (2012) In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model. Cancer Gene Ther 19(8):523-529
  2. Dervisis NG et al (2007) Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma. J Am Vet Med Assoc 231(4):563-569
  3. Spiro T et al (2000) New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance. Forum (Genova) 10(3):274-285